Glenmark’s US subsidiary reaches $15.3M settlement with Humana
The U.S. subsidiary of Glenmark Pharmaceuticals will pay Humana nearly $15.3 million in the wake of antitrust and consumer protection lawsuits. Glenmark disclosed the settlement in an Aug. 11 filing with the National Stock Exchange of India. The document said the company faced allegations of price-fixing, market allocation and anticompetitive behavior in more than 35 […] The post Glenmark’s US subsidiary reaches $15.3M settlement with Humana appeared first on Becker's Payer Issues | Payer News .
View related coverage on the timeline →
Useful signal?
Sign in with GitHub below to react 👍 / 👎, or comment if a category looks wrong — your reactions help curate this feed. How feedback works
Draft Insight Angle
Auto-generated draft — review and edit before any external use.
Humana — policy / regulatory changes. Via Becker's Payer Issues.
Analytic angles
- Compare against the current CMS rate/bid-cycle documents.
- Single-source so far — corroborate against a second outlet.
Draft paragraph
[DRAFT — verify before any external use] Becker's Payer Issues reports on policy / regulatory changes involving Humana: The U.S. subsidiary of Glenmark Pharmaceuticals will pay Humana nearly $15.3 million in the wake of antitrust and consumer protection lawsuits. Glenmark disclosed the settlement in an Aug. 11 filing with the National Sto…
Note: This is an early signal based on public reporting. Confirm against primary sources before drawing conclusions. Market dynamics may shift as additional information emerges.